Yong Cang

Company: Degron Therapeutics

Job title: Chief Scientific Officer & Co-founder

Seminars:

Debating if Molecular Glues Will Stick as the Next Modality for DDR Inhibition to Improve Therapeutic Window 2:30 pm

Disrupt small molecule approaches for DDR inhibition Molecular glues as a growing novel modality in oncology and DDR inhibition Unlock a new era and targeting specific non-catalytic proteins in DDR pathwaysRead more

day: Day One Track A PM